Head-to-head evidence
MET-097i vs Supaglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
MET-097i
Developed by Pfizer
NCT06897202 · Phase 2 · completed
The trial randomly assigned 133 participants to MET097 or placebo and was double-blinded, with percent change in body weight as the primary clinical endpoint. However, because no primary efficacy results are available, it is not possible to determine whether the endpoint was met.
Figures from conference coverage of the ADA 2026 presentation; weight change is from baseline, not placebo-adjusted, and no significance testing was reported for the weight endpoint. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2027 · NCT07400653 (registry estimate)
Supaglutide
Developed by Shanghai Yinnuo Pharmaceutical Technology
NCT04998032 · Phase 2/3 · completed
In this randomized, double-blind, placebo-controlled Phase 2b/3 trial in 620 adults with type 2 diabetes already taking metformin, adding once-weekly supaglutide significantly lowered blood-sugar control (HbA1c) at 24 weeks compared with adding placebo, with a clearly significant treatment difference.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MET-097i's landscape · Supaglutide's landscape